Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.66 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.66 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.66 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.66 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.66 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.66 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.66 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.66 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.66 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.66 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.66 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.66 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.66 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.66 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.66 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.66 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.66 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.66 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.66 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147711 | 0.98 | SLC6A2 (0.68) | LMNASMN1; SMN2PMP22KDM4EMAPK1 | |
| Hydrochloric Acid SCHEMBL29518940 | 0.92 | LMNA (0.59) | LMNASMN1; SMN2PMP22KDM4EMAPK1 | |
| Diphenhydramine SCHEMBL28188903 | 0.86 | SLC6A2 (0.83) | LMNASMN1; SMN2PMP22KDM4EMAPK1 | |
| SCHEMBL8127960 | 0.85 | LMNA (0.56) | LMNASMN1; SMN2PMP22KDM4EMAPK1 | |
| SCHEMBL7688529 | 0.84 | CYP2D6 (0.74) | LMNASMN1; SMN2PMP22KDM4EMAPK1 | |
| SCHEMBL7570154 | 0.82 | LMNA (0.55) | LMNASMN1; SMN2PMP22KDM4EMAPK1 | |
| SCHEMBL2553732 | 0.82 | SLC6A2 (0.71) | LMNASMN1; SMN2PMP22KDM4EMAPK1 | |
| SCHEMBL13302845 | 0.82 | SLC6A2 (0.66) | LMNASMN1; SMN2PMP22KDM4EMAPK1 | |
| SCHEMBL8137373 | 0.82 | LMNA (0.52) | LMNASMN1; SMN2PMP22KDM4EMAPK1 | |
| Diphenhydramine SCHEMBL10487818 | 0.81 | LMNA (1.00) | LMNASMN1; SMN2PMP22KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119946496-A | Low-frequency underwater acoustic transducer with double-antipodal signal excitation function and method | 杭州仁牧科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-116973496-A | High-throughput quality detection method for lung-heat clearing and toxin expelling particles | 中国科学院大连化学物理研究所 | 2023-10-31 | — | — | CN | claimed |
| US-11285153-B2 | Substituted pyrimidine piperazine compound and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-03-29 | — | — | US | claimed |
| US-20220074923-A1 | METHODS OF IDENTIFYING PARKIN-MEDIATED MITOPHAGY ACTIVATING AGENTS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2022-03-10 | — | — | US | claimed |
| CN-119970772-B | Application of tectoridin B in preparation of medicine for preventing and/or treating toxoplasma infection | 广东医科大学附属医院 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130908-A1 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4695308-A1 | ENGINEERED ANTIBODIES AND USES THEREOF | Invitrogen BioServices India Private Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| US-12544375-B2 | Small molecule therapeutic for parkinson's disease paired with a biomarker of therapeutic activity | THE BOARD OF TRUSTEES OF THE LELAND JUNIOR UNIVERSITY (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260014184-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4633645-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | University College Cardiff Consultants Limited (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-12378576-B2 | Gene therapy for CNS degeneration | SPACECRAFT SEVEN, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-12351611-B2 | Molecules for organelle-specific protein delivery | LARIMAR THERAPEUTICS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20090258050-A1 | Controlled Drug Delivery Using a Zein Layer Modified with Levulinic Acid | MED INSTITUTE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20080178459-A1 | METHOD OF PRODUCING A RADIALLY EXPANDABLE PROSTHESIS | COOK INCORPORATED (US) | 2008-07-31 | — | — | US | disclosed |
| US-20070299518-A1 | Device with nanocomposite coating for controlled drug release | MED INSTITUTE, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070207184-A1 | Implantable medical device coated with a bioactive agent | MED INSTITUTE, INC (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070207183-A1 | Zein coated medical device | MED INSTITUTE, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070196423-A1 | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent | MED INSTITUTE, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070182055-A1 | Inline application of coatings | COOK INCORPORATED (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070043423-A1 | Intraluminal device with a hollow structure | MED INSTITUTE INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544375-B2 | Small molecule therapeutic for parkinson's disease paired with a biomarker of therapeutic activity | PINK1, SNCA, AIFM1 | SLC6A2 1326/4885SLC6A4 1994/4885SLC6A3 273/4885 |
| US-20090258050-A1 | Controlled Drug Delivery Using a Zein Layer Modified with Levulinic Acid | LTN1, LOXL2, LOXL1 | SLC6A2 2718/4885SLC6A4 3022/4885SLC6A3 3815/4885 |
| US-20260130908-A1 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | SHMT2, NLN, TFAM | SLC6A2 527/4885SLC6A4 537/4885SLC6A3 998/4885 |
| US-20260014184-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | ADRM1, ADORA1, ADORA2A | SLC6A2 473/4885SLC6A4 450/4885SLC6A3 583/4885 |
| US-11285153-B2 | Substituted pyrimidine piperazine compound and use thereof | HTR5A, TPH1, HTR2C | SLC6A2 29/4885SLC6A4 13/4885SLC6A3 59/4885 |
| US-20070207183-A1 | Zein coated medical device | PCSK9, ZYX, ZFX | SLC6A2 2846/4885SLC6A4 4011/4885SLC6A3 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.